Dr. Adi Zuloff-Shani reports

CLEARMIND MEDICINE COMPLETED TYPE A MEETING WITH THE FDA

Clearmind Medicine Inc. has completed a Type A meeting with the United States Food and Drug Administration (FDA) to discuss the company's clinical trial of its proprietary MEAI (5-methoxy-2-aminoindane)-based CMND-100 compound, for the treatment of alcohol use disorder (AUD) using its novel psychedelic-based therapy.

"We're pleased to report we recently met with the FDA to align on the content of our IND [investigational new drug] resubmission for CMND-100," said Dr. Adi Zuloff-Shani, chief executive officer of Clearmind Medicine. "The meeting was informative and productive, and we're eager to advance the U.S. regulatory process and potentially bring a new hope for millions suffering from AUD by providing an innovative approach to overcome the challenges associated with the current available treatments to date."

The active ingredient in CMND-100 is MEAI, a novel psychoactive molecule that has been reported to reduce the desire to consume alcoholic beverages while exerting a euphoric alcohol-like experience. MEAI was found to interact with the serotonergic receptors 5-HT1a, 5-HT2a and 5-HT2b. The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference and dependence. MEAI was also found to interact with the alpha-2-adrenergic receptors alpha2A, alpha2B and alpha2C, and the plasma membrane monoamine transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT) -- these are believed to participate in mediating alcohol drinking behaviour, and therefore could constitute important molecular targets for interventions that target drugs of abuse such as alcohol.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The company's intellectual portfolio currently consists of 15 patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

We seek Safe Harbor.